Aethlon Medical Inc. Announces New Clinical Study Highlighting Hemopurifier's Ability to Remove Platelet-Derived Extracellular Vesicles in Ongoing Oncology Trial

Reuters
14 May
<a href="https://laohu8.com/S/AEMD">Aethlon Medical Inc</a>. Announces New Clinical Study Highlighting Hemopurifier's Ability to Remove Platelet-Derived Extracellular Vesicles in Ongoing Oncology Trial

Aethlon Medical Inc., a medical therapeutic company focused on developing products for cancer and life-threatening infectious diseases, has announced the publication of preclinical data showcasing the Hemopurifier®'s ability to remove platelet-derived extracellular vesicles (PD-EVs) from plasma. This breakthrough supports their ongoing oncology clinical trial in Australia, as PD-EVs are known to contribute to the spread of cancer. The study, published on bioRxiv, highlights the Hemopurifier's potential across multiple indications, suggesting a "pipeline within a device" approach for future therapeutic applications. Aethlon Medical plans to submit these findings to a peer-reviewed journal and further investigate PD-EV removal in diseases of interest.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87101) on May 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10